Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Am J Transplant ; 2019 Dec 13.
Artigo em Inglês | MEDLINE | ID: mdl-31834977

RESUMO

Epipericardial fat necrosis is an uncommon clinical condition of unknown etiology. It typically presents as acute pleuritic chest pain and should be differentiated from acute pulmonary embolism and acute coronary syndrome. This condition is diagnosed by characteristic chest computed tomography findings of an ovoid mediastinal fatty lesion with intrinsic and surrounding soft-tissue stranding. Treatment of epipericardial fat necrosis includes the administration of anti-inflammatory agents, and symptoms usually resolve within a few days after treatment initiation. This disease entity has rarely been reported since it was first described in 1957. Most current knowledge of epipericardial fat necrosis is based on case reports that describe this condition in previously healthy individuals. We present the case of a 39-year-old woman with a history of heart transplant, who presented with chest pain secondary to epipericardial fat necrosis. Serial computed tomography revealed lesion resolution after appropriate treatment.

2.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 29(3 Supl): 287-290, jul.-set. 2019.
Artigo em Português | LILACS | ID: biblio-1023063

RESUMO

Existem poucos sistemas de avaliação de mortalidade após transplante cardíaco (TC) que se baseiem em fatores relacionados com o doador e que sejam capazes de predizer o prognóstico. Identificar características dos doadores que têm impacto na sobrevida depois do TC pode contribuir para melhorar os resultados e a alocação de órgãos. Aplicamos um sistema de avaliação americano para predizer a mortalidade pós-TC em uma coorte brasileira. Objetivo: Avaliar um escore americano como preditor de mortalidade depois de TC em uma coorte brasileira. Métodos: Análise de uma base de dados de um centro de TC brasileiro de 2013 a 2015. Foram avaliadas quatro características dos doadores: tempo de isquemia, idade do doador, discordância racial doador/receptor e a função renal do doador. A sobrevida foi estimada pelo teste de log-rank em faixas de pontuação pré-determinadas. Resultados: Foram 110 doadores, 89% homens e 62% brancos. A principal causa de morte foi trauma (66,6%). Os doadores tinham em média 29,8 anos, 18,6 de relação Nitrogênio da ureia sanguínea / Creatinina, 175 minutos de tempo de isquemia e 42% de discordância racial com o receptor. Não houve diferença de sobrevida entre as faixas de pontuação. Conclusão: Apesar de preditor de mortalidade após transplante cardíaco em uma população americana, esse escore não foi útil para uma coorte de transplante brasileira. As diferenças, inclusive a alta taxa de miscigenação pode ser uma explicação para esses achados


here are few systems to assess mortality after heart transplantation (CT) that are based on donor-related factors and can predict prognosis. Identifying donor characteristics that impact post-CT survival can contribute to improved outcomes and organ allocation. We applied a US evaluation system to predict mortality after CT in a Brazilian cohort. Objective: To evaluate an American score as a predictor of mortality following CT in a Brazilian cohort. Method: Database analysis of a Brazilian CT center from 2013 to 2015. Four donor characteristics were evaluated: ischemia time, donor age, donor-recipient race mismatch, and donor renal function. Survival was estimated by the log-rank test in predetermined score ranges. Results: There were 110 donors, 89% male and 62% white. The main cause of death was trauma (66.6%). Donors had a mean age of 29.8 years, a mean blood urea nitrogen / creatinine ratio of 18.6, a mean ischemia time of 175 minutes, and race mismatch with the recipient of 42%. There was no difference in survival between the score ranges. Conclusion: Although it was a predictor of mortality after cardiac transplantation in an American population, this score was not useful for a Brazilian transplant cohort. Differences, including the high rate of miscegenation, may explain these findings


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Doadores de Tecidos , Transplante/mortalidade , Transplante de Coração/mortalidade , Prognóstico , Doenças Cardiovasculares , Análise de Sobrevida , Prevalência , Valor Preditivo dos Testes , Estudos de Coortes , Resultado do Tratamento , Insuficiência Cardíaca/terapia
4.
Methodist Debakey Cardiovasc J ; 15(4): 267-273, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31988687

RESUMO

Recent decades have seen an increase in survival rates for cancer patients, partially explained by earlier diagnoses and new chemotherapeutic agents. However, chemotherapy may be associated with adverse cardiovascular events, including hypertension and pulmonary hypertension, supraventricular and ventricular arrhythmias, cardiomyopathy, and other forms of cardiovascular disease. For patients, the benefits of chemotherapy may be partially obfuscated by deleterious effects on the cardiovascular system, resulting in a significant increase in morbidity and mortality. In this article, we review strategies for prevention and treatment of chemotherapy-related cardiotoxicity.

7.
J Am Coll Cardiol ; 71(20): 2281-2290, 2018 05 22.
Artigo em Inglês | MEDLINE | ID: mdl-29540327

RESUMO

BACKGROUND: Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with ß-blockers remains controversial. OBJECTIVES: This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity. METHODS: The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m2) to receive carvedilol or placebo until chemotherapy completion. The primary endpoint was prevention of a ≥10% reduction in LVEF at 6 months. Secondary outcomes were effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction. RESULTS: Primary endpoint occurred in 14 patients (14.5%) in the carvedilol group and 13 patients (13.5%) in the placebo group (p = 1.0). No differences in changes of LVEF or B-type natriuretic peptide were noted between groups. A significant difference existed between groups in troponin I levels over time, with lower levels in the carvedilol group (p = 0.003). Additionally, a lower incidence of diastolic dysfunction was noted in the carvedilol group (p = 0.039). A nonsignificant trend toward a less-pronounced increase in LV end-diastolic diameter during the follow-up was noted in the carvedilol group (44.1 ± 3.64 mm to 45.2 ± 3.2 mm vs. 44.9 ± 3.6 mm to 46.4 ± 4.0 mm; p = 0.057). CONCLUSIONS: In this largest clinical trial of ß-blockers for prevention of cardiotoxicity under contemporary ANT dosage, the authors noted a 13.5% to 14.5% incidence of cardiotoxicity. In this scenario, carvedilol had no impact on the incidence of early onset of LVEF reduction. However, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction. (Carvedilol Effect in Preventing Chemotherapy-Induced Cardiotoxicity [CECCY]; NCT01724450).


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Antineoplásicos/efeitos adversos , Cardiotoxicidade/diagnóstico por imagem , Cardiotoxicidade/prevenção & controle , Carvedilol/uso terapêutico , Adulto , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/epidemiologia , Cardiotoxicidade/epidemiologia , Método Duplo-Cego , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos
10.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 24(3): 54-61, jul.-set.2014.
Artigo em Português | LILACS | ID: lil-763798

RESUMO

O transplante cardíaco é reconhecido como o melhor tratamentopara a insuficiência cardíaca refratária. O Brasil tem um grandepotencial de aumento do número de transplantes, já que atualmenteo aproveitamento dos potenciais doadores é muito baixo. Os pioresresultados do transplante aqui, quando comparados aos dadosinternacionais, decorrem, em parte, da associação de doadorespior cuidados e receptores mais graves, com limitação de acessoaos dispositivos de assistência circulatória. O desenvolvimento decentros transplantadores capazes de melhorar a condição clínicados receptores e de criar condições para aumentar a efetivaçãodos doadores pode ter um impacto positivo no número e nosresultados dos transplantes. A organização do Heart Team, umaequipe multidisciplinar envolvendo profissionais com funçõescomplementares, é essencial para o aprimoramento não só do cuidadoao receptor, mas também de todo o processo envolvido no transplantecardíaco, incluindo a captação de órgãos. A equipe deve ser compostapor cardiologistas clínicos e cirurgiões cardiovasculares dedicadosao transplante cardíaco, outros especialistas (como intensivistas,infectologistas e patologistas) fundamentais no cuidado do receptor,enfermeiros e biomédicos envolvidos na avaliação e cuidado dosdoadores e na captação do órgão, enfermeiros dedicados à assistênciados receptores e uma equipe multidisciplinar envolvida em todo oprocesso, desde a avaliação do paciente com insuficiência cardíacarefratária, potencial candidato ao transplante, até o seguimento esuporte do transplantado cardíaco e seus familiares. Esta abordagemcompleta e harmoniosa que o Heart Team possibilita é certamente ocaminho para o crescimento do transplante cardíaco no Brasil.


Heart transplant is recognized as the treatment of choice forrefractory heart failure. Brazil has a great potential to increase thenumber of heart transplants, as the use of potential donors is nowtoo low. The worst results of heart transplants in Brazil, comparedwith international data, may be, in part, due to the association ofpoor care of donors and poor conditions of recipients, with limitedaccess to circulatory assistance devices. The development of hearttransplant centers capable of improving the clinical conditions ofthe recipients and creating ways to increase the use of donors mayhave a positive impact in the number and results of transplants. Theorganization of a “Heart Team”, a multidisciplinary team evolvingprofessionals with complementary functions, is essential not only toimprove the care of recipients, but also to improve the whole processof heart transplant, including organ harvesting. The team must becomposed of cardiologists and cardiovascular surgeons dedicated toheart transplant, other specialists (such as intensivists, infectologistsand pathologists) who have a crucial role in the care of recipients;nurses and biomedicals evolved in the evaluation and care of donorsand in organ harvesting; nurses dedicated in recipients assistanceand a multidisciplinary team evolved in the whole process, sincethe evaluation of the patient with refractory heart failure, a potentialcandidate for heart transplant, up to the follow-up and support ofheart transplanted patients and their families. This complete andharmonious approach that “Heart Team” enables is certainly theway to improve heart transplant in Brazil.


Assuntos
Humanos , Insuficiência Cardíaca/cirurgia , Insuficiência Cardíaca/diagnóstico , Transplante de Coração/reabilitação , Coleta de Tecidos e Órgãos/métodos , Equipe de Assistência ao Paciente/ética , Seleção do Doador/métodos
11.
Cardiovasc Pathol ; 21(4): 358-60, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22153556

RESUMO

Hunter syndrome (MPSII) is a rare X-linked lysosomal storage disorder that can affect multiple systems but primarily affects the heart. We report the case of a previously asymptomatic 23-year-old patient who had an attenuated form of MPSII and presented with refractory heart failure that required a heart transplant. The diagnosis was confirmed by detection of an increase in urinary excretion of glycosaminoglycans, a deficiency in enzymatic activity, and molecular analysis. A myocardial biopsy revealed hypertrophic cardiomyocytes, mild fibrosis, and lysosomal storage in interstitial cells. Molecular analysis identified a novel mutation in the iduronate-2-sulfatase gene. Although the clinical outcome was not favorable, we believe that this approach may be valid in end-stage heart failure.


Assuntos
Insuficiência Cardíaca/cirurgia , Mucopolissacaridose II/cirurgia , Ecocardiografia Doppler , Saúde da Família , Evolução Fatal , Feminino , Fibrose/complicações , Fibrose/patologia , Insuficiência Cardíaca/etiologia , Transplante de Coração , Humanos , Hipertrofia , Lisossomos/patologia , Masculino , Mucopolissacaridose II/complicações , Mucopolissacaridose II/diagnóstico , Mutação , Miócitos Cardíacos/patologia , Sulfotransferases/genética , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA